Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

NCT03007030 PHASE2 RECRUITING

This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	PHASE2
Status	RECRUITING
Enrolment	55
Start date	Wed Apr 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• CD30-Positive Neoplastic Cells Present
• Malignant Mesothelioma

Interventions

• Brentuximab Vedotin
• Laboratory Biomarker Analysis

Countries

United States